Dr. Hönle Management

Dr. Markus Arendt is Managing Director and Chairman of the Management Board of Dr. Hönle AG from May 01, 2024 and serves as its Chief Executive Officer since 2024.

Board Members

Name	Position	Tenure	Compensation	Ownership
Franz Richter	Chairman of Supervisory Board	less than a year	€379.40k	no data
Bernhard Gimple	Independent Deputy Chairman of Supervisory Board	9.7yrs	€30.00k	no data
Imke Libon	Independent Member of Supervisory Board	3.5yrs	€30.00k	no data
Niklas Friedrichsen	Supervisory Board Member	less than a year	€43.00k	no data
Melanie Ott	Independent Member of Supervisory Board	no data	no data	no data

2.0yrs

Average Tenure

56yo

Average Age

Experienced Board: HNL's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Dr. Hönle Management

Management criteria checks 0/4

Key information

Recent management updates

Dr. Hönle AG Announces Management Changes

Dr. Hönle AG, Annual General Meeting, Mar 23, 2023

Norbert Haimerl Becomes CEO of Dr. Hönle AG

Dr. Hönle AG, Annual General Meeting, Mar 24, 2022

Dr. Hönle AG, Annual General Meeting, Mar 23, 2021

Recent updates

Dr. Hönle AG to Report First Half, 2025 Results on May 08, 2025

The Price Is Right For Dr. Hönle AG (ETR:HNL) Even After Diving 26%

Third quarter 2024 earnings released: €0.044 loss per share (vs €1.52 loss in 3Q 2023)

Why Investors Shouldn't Be Surprised By Dr. Hönle AG's (ETR:HNL) P/S

Is There An Opportunity With Dr. Hönle AG's (ETR:HNL) 50% Undervaluation?

Price target decreased by 14% to €25.20

Second quarter 2024 earnings released: EPS: €0.03 (vs €0.11 in 2Q 2023)

First quarter 2024 earnings released: €0.15 loss per share (vs €0.26 profit in 1Q 2023)

Price target decreased by 7.9% to €29.15

Dr. Hönle AG's (ETR:HNL) Popularity With Investors Is Clear

Dr. Hönle AG to Report Q1, 2024 Results on Feb 26, 2024

Dr. Hönle Ag Provides Earnings Guidance for the Year 2022/2023 and 2023/2024

Now 21% undervalued after recent price drop

Dr. Hönle AG Announces Management Changes

Dr. Hönle AG to Report Fiscal Year 2023 Results on Dec 07, 2023

We Think Dr. Hönle (ETR:HNL) Has A Fair Chunk Of Debt

New minor risk - Market cap size

Now 21% undervalued after recent price drop

Price target decreased by 14% to €31.65

Third quarter 2023 earnings released: €1.52 loss per share (vs €0.12 loss in 3Q 2022)

Is It Too Late To Consider Buying Dr. Hönle AG (ETR:HNL)?

Now 23% undervalued

Is Dr. Hönle (ETR:HNL) A Risky Investment?

Second quarter 2023 earnings released: EPS: €0.11 (vs €0.36 in 2Q 2022)

Full year 2022 earnings released: €2.20 loss per share (vs €0.80 loss in FY 2021)

Dr. Hönle AG to Report Q3, 2023 Results on Aug 07, 2023

Dr. Hönle AG, Annual General Meeting, Mar 23, 2023

An unknown buyer acquired Raesch Quarz (Germany) GmbH from Dr. Hönle AG (XTRA:HNL).

The Returns On Capital At Dr. Hönle (ETR:HNL) Don't Inspire Confidence

Dr. Hönle AG to Report Fiscal Year 2022 Results on Dec 08, 2022

Dr. Hönle (ETR:HNL) Has No Shortage Of Debt

Norbert Haimerl Becomes CEO of Dr. Hönle AG

Third quarter 2022 earnings released: €0.12 loss per share (vs €0.021 profit in 3Q 2021)

Dr. Hönle AG Provides Earnings Guidance for 2022

Price target decreased to €44.75

There Are Reasons To Feel Uneasy About Dr. Hönle's (ETR:HNL) Returns On Capital

Price target decreased to €57.00

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Dr. Hönle Ag Provides Earnings Guidance for 2022

Upcoming dividend of €0.20 per share

Dr. Hönle AG, Annual General Meeting, Mar 24, 2022

Price target decreased to €59.50

Capital Allocation Trends At Dr. Hönle (ETR:HNL) Aren't Ideal

Dr. Hönle AG Provides Earnings Guidance for the Financial Year 2021/2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall to €1.20

Third quarter 2021 earnings released: EPS €0.021 (vs €0.065 in 3Q 2020)

Consensus EPS estimates fall to €1.91

Dr. Hönle AG (ETR:HNL) Shares Could Be 37% Below Their Intrinsic Value Estimate

Is Dr. Hönle (ETR:HNL) A Risky Investment?

Is Dr. Hönle AG (ETR:HNL) Potentially Undervalued?

Dr. Hönle (ETR:HNL) Could Be Struggling To Allocate Capital

Second quarter 2021 earnings released

Calculating The Fair Value Of Dr. Hönle AG (ETR:HNL)

Upcoming Dividend of €0.50 Per Share

Do Investors Have Good Reason To Be Wary Of Dr. Hönle AG's (ETR:HNL) 1.0% Dividend Yield?

We Think Dr. Hönle (ETR:HNL) Is Taking Some Risk With Its Debt

First quarter 2021 earnings released: EPS €0.27 (vs €0.48 in 1Q 2020)

New 90-day low: €47.40

Is It Too Late To Consider Buying Dr. Hönle AG (ETR:HNL)?

We Wouldn't Rely On Dr. Hönle's (ETR:HNL) Statutory Earnings As A Guide

Full year 2020 earnings released: EPS €1.02 (vs €2.24 in FY 2019)

Earnings beat expectations, revenue disappoints

Did Business Growth Power Dr. Hönle's (ETR:HNL) Share Price Gain of 131%?

Should We Be Excited About The Trends Of Returns At Dr. Hönle (ETR:HNL)?

What Kind Of Investors Own Most Of Dr. Hönle AG (ETR:HNL)?

Dr. Hönle AG (ETR:HNL) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Is Dr. Hönle AG (ETR:HNL) An Attractive Dividend Stock?

Dr. Hönle AG to Report Fiscal Year 2020 Results on Jan 28, 2021

These 4 Measures Indicate That Dr. Hönle (ETR:HNL) Is Using Debt Extensively